Nuformix global licensing agreement with Oxilio with Quotient Sciences supporting

Nuformix plc, a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announce that following the Company’s signing of an exclusive global licensing agreement with Oxilio Ltd for NXP001 on 13 September 2021, Oxilio has progressed the product and signed a significant service contract with Quotient Sciences Ltd to support the formulation development of NXP001. NXP001 is a proprietary new form of aprepitant which is currently marketed for cancer chemotherapy induced nausea and vomiting.

Under the contract Oxilio will work with Quotient Sciences, a drug development and manufacturing accelerator, to identify and evaluate the cocrystal formulation of aprepitant to deliver optimal bioavailability for the treatment of CINV.

Nuformix plc (LON:NFX) is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology using drug repurposing.

Click to view all articles for the EPIC: NFX
Or click to view the full company profile:
Nuformix plc

Nuformix Executive Director discusses patent updates, interim results and future plans (LON:NFX)

25th June 2024

Nuformix plc (LON:NFX) Executive Director Dr. Dan Gooding caught up with DirectorsTalk for an exclusive interview to discuss recent patents for NXP002 & NXP004, highlights from interim results, and what’s next for the company and its

Nuformix Secures Key Patents and Outlines Future Plans for NXP002 and NXP004 (VIDEO)

18th June 2024

Nuformix Plc (LON:NFX), a pharmaceutical development company focused on drug repurposing for fibrosis and oncology, recently provided a patent update for its NXP002 and NXP004 programs, as well as its interim results. In this interview with Nuformix

Nuformix continues to advance and exploit current assets within the portfolio

18th June 2024

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced its unaudited results for the six months ended 31 March 2024. Operational highlights (including post-period end) · The Board continues

Nuformix plc Innovative Drug Repurposing with Breakthroughs in Fibrosis and Oncology

3rd January 2024

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced its audited results for the eighteen months ended 30 September 2023 following the change in the Company’s accounting reference

Nuformix Plc Receives Second NXP001 Milestone Payment from Oxilio

18th December 2023

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that the Company has achieved the second milestone according to its updated NXP001 exclusive licensing agreement with Oxilio

Nuformix plc Official Decision to Grant from the Japanese Patent Office

23rd October 2023

Nuformix plc (LON: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that it has been issued with an Official Decision to Grant Notice of Allowance for Japanese National Phase

Nuformix now focusing on out-licencing NXP002 & NXP004 (LON:NFX)

28th September 2023

Nuformix’s Dan Gooding discusses the revised agreement with Oxilio for NXP001 and the progress on NXP002 & NXP004 in this exclusive interview with DirectorsTalk.

Nuformix excited as it moves focus to NXP002 and NXP004 programmes

19th September 2023

Nuformix plc (LON:NFX) Executive Director Dan Gooding joins DirectorsTalk to discuss an update on its NXP001 exclusive licensing agreement. In this interview Dr Dan Gooding outlines what the revised agreement covers, explains what it means for Nuformix

Nuformix receives new NXP001 development milestone payments in updated Oxilio agreement

18th September 2023

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that the Company is to receive new immediate and near-term undisclosed milestone payments as part of an update

Nuformix hosting online Q&A session on 13 June 2023

2nd June 2023

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that the Company’s Executive Director, Dr Dan Gooding, will be hosting an online Q&A session at 5.30

Nuformix appoints Kreston Reeves as auditor

25th May 2023

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the appointment of Kreston Reeves LLP as auditor to the Company. The appointment of Kreston Reeves

Nuformix plc has a complete pre-clinical story for potential licensing partners (VIDEO)

22nd May 2023

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced its unaudited results for the twelve months ended 31 March 2023 following the change in the Company’s accounting reference

Nuformix continuing to generate value-adding data for its lead programme

22nd May 2023

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced its unaudited results for the twelve months ended 31 March 2023 following the change in the Company’s accounting

Nuformix delighted with NXP002 study results

18th May 2023

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the following update regarding the Company’s NXP002 programme, a proprietary new form of tranilast, being developed as a

Nuformix to raise £70,000 through subscription, to progress NXP002

17th April 2023

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced a subscription to raise gross proceeds of £70,000 through a subscription for 35,000,000 new ordinary shares

Be sure to check our sister interview main ratings news website